Home - Gastroenterology Advisor
WEBCyclic Vomiting Syndrome: AGA Issues Practice Update on Diagnosis and Management. By Allison Nguyen, PharmD. The American Gastroenterological Association has outlined updated guidance on the management of cyclic vomiting syndrome.
Clinician Insights on How to Manage Semaglutide-Induced …
WEBSep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
What We Know About Semaglutide Adverse Events and …
WEBSep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
FDA Limits Authorized Use of COVID-19 PrEP Therapy Pemgarda
WEB21 hours ago · The Food and Drug Administration (FDA) has revised the Emergency Use Authorization (EUA) for Pemgarda (pemivibart), a SARS-CoV-2 spike protein-directed attachment inhibitor authorized for the preexposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg. The treatment is specifically for patients who are not currently infected with SARS-CoV-2 ...
Intestinal Ultrasound for IBD: Clinical Practice Update From the AGA
WEBAug 2, 2024 · The American Gastroenterological Association (AGA) released a clinical practice update in Clinical Gastroenterology and Hepatology about the role of intestinal ultrasound (IUS) in the management of inflammatory bowel diseases (IBDs).. The primary objectives in IBD management are to reverse endoscopically evident inflammation, maintain long-term remission, and to avoid complications.
Tradipitant Relieves Nausea, Other Gastroparesis Symptoms
WEBTradipitant is efficacious for relieving nausea and other gastroparesis symptoms. Tradipitant significantly improved nausea and other symptoms in patients with idiopathic and diabetic gastroparesis compared with placebo, according to study results presented at the American College of Gastroenterology (ACG) 2022 Annual Meeting, held from October ...
Short-Acting GLP-1 RAs May Increase GERD, Barrett Esophagus …
WEBMay 12, 2023. Short-acting GLP-1 receptor agonists are associated with increased risk for GERD and Barrett esophagus among patients with type 2 diabetes. Short-acting glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are associated with increased risk for developing gastroesophageal reflux disease (GERD) and its associated complications ...
Dupilumab Safely Improves EoE Symptoms, Regardless of Prior ...
WEBOct 25, 2022 · Dupilumab safely and efficaciously improved clinical, histologic, endoscopic, and symptomatic measures of eosinophilic esophagitis (EoE), regardless of previous treatment with swallowed topical corticosteroids (STCs), according to study results presented at the American College of Gastroenterology (ACG) 2022 Annual Meeting, held from October 21 to 26, 2022, in Charlotte, North Carolina, and ...
Systemic Glucocorticoid Therapy Linked to Elevated Risk for New …
WEB2 days ago · Exposure to systemic glucocorticoids more than doubles the risk for new-onset diabetes among hospitalized patients, according to the results of a study presented at the 60th Annual Meeting of the European Association for the Study of Diabetes, held from September 9 to 13, 2024 in Madrid, Spain.
GLP-1RA Use May Increase Risk for Gastric Residue, Especially in T2D
WEBJun 4, 2024 · The analysis included 306 patients using GLP-1RAs matched with 306 GLP-1RA-negative control individuals. Of the 612 paired patients (median age, 61 years; median body mass index [BMI], 32.6 kg/m 2), 89% had a history of T2D.. Among the participants, 55 (9%) had gastric residue, which was greater in GLP-1RA users and in all T2D groups regardless of T2D complications or insulin use.
Skip to content